The government of Puerto Rico seems to not be paying attention to all the comments, positions and recommendations given by the cannabis industry, and it’s taking questionable decisions while making the new cannabis bill. Members of the Medical Cannabis Industry expressed their concern about this situation and are raising their voice looking for more recognition by the government.
The Association of Members of the Medical Cannabis Industry (MICaM) expressed concern about the prompt approval of bills that seek to amend the law regulating the cannabis industry in Puerto Rico, without the input of said industry.
Among those proposals is Senate Bill 1317, which was approved by the House of Representatives with some amendments, so it will be evaluated in the Conference Committee during the coming weeks for approval.
For the cannabis industry, the process of discussion and approval of these amendments has been hastened, while they wait for the actual decision, and the legislature has not taken into consideration their written comments, positions, and recommendations on the subject.
If you want to know more about cannabis, how Puerto Rico’s cannabis industry is struggling with the government in order to make a bil that adjusts to its necessities, and to find out the latest hemp news, download the Hemp.im mobile application.
Puerto Rico’s government is approving laws without any input from the cannabis industry
“To our surprise, these cannabis bills moved forward in the congress without considering our input at all, after we presented the industry’s comments, concerns, and recommendations in writing to the legislators, in order to make a bill that adjusts to our necessities. We don’t know who is pushing for the approval of these measures behind the scenes, but they are certainly putting a lot of pressure on the cannabis sector” said Association President Jose Rivera Jimenez.
One of the issues of greatest concern to the organization is the amendment that prohibits a cannabis industry member of any company from being a member of the Medicinal Cannabis Regulatory Board. That excludes from the regulatory process those who really know the challenges, obstacles, and problems faced by this growing sector and could put their knowledge in use to push the industry forward.
“Currently, most members of the Medicinal Cannabis Regulatory Board are agency heads, who in addition to being very busy in their respective roles, know very little about what goes on in the day-to-day operations of the cannabis establishments around the country. There needs to be representation from all industry members on that body so that there can be a link to the realities we live with every day and the struggles of the sector” added Rivera.
The cannabis industry is struggling with the government for representation
The Association of Members of the Medical Cannabis Industry (MICaM) indicated that it is imperative that the Regulatory Board has adequate representation of the cannabis industry members so that this body can comply with a coherent and balanced regulatory process focused on the best welfare of patients.
The Association is not aware at this time of the scope of the amendments made by the House of Representatives to Senate Bill 1317. For that reason, they are calling on legislators not to concur with the amendments and on the governor not to sign the amendments until their concerns are discussed and addressed.
One of MICaM’s recommendations is to create an Advisory Body, composed of active members from different sectors of the industry, to address technical issues and provide timely suggestions to the Regulatory Board.
“Without this representative element, the Board will not be able to exercise its functions with the seriousness and efficiency required. We hope they will take us into consideration before the final approvals of the measure, and ultimately we call on the Governor not to endorse the changes without our input and that of the patient community,” Rivera concluded.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in TeleMundoPR, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.